Ilya Yakavets

Dr. Ilya Yakavets

University of Toronto, Department of Chemistry
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2017 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
MMMarie Millard
Marie Millard
Ilya YakavetsIlya Yakavets
Ilya Yakavets
VZVladimir Zorin
Vladimir Zorin
AKAigul Kulmukhamedova
Aigul Kulmukhamedova
SMSophie Marchal
Sophie Marchal
LBLina Bezdetnaya
Lina Bezdetnaya
The increasing number of publications on the subject shows that nanomedicine is an attractive field for investigations aiming to considerably improve anticancer chemotherapy. Based on selective tumor targeting while sparing healthy tissue, carrier-mediated drug delivery has been expected to provide significant benefits to patients. However, despite reduced systemic toxicity, most nanodrugs approved for clinical use have been less effective than previously anticipated. The gap between experimental results and clinical outcomes demonstrates the necessity to perform comprehensive drug screening by using powerful preclinical models. In this context, in vitro three-dimensional models can provide key information on drug behavior inside the tumor tissue. The multicellular tumor spheroid (MCTS) model closely mimics a small avascular tumor with the presence of proliferative cells surrounding quiescent cells and a necrotic core. Oxygen, pH and nutrient gradients are similar to those of solid tumor. Furthermore, extracellular matrix (ECM) components and stromal cells can be embedded in the most sophisticated spheroid design. All these elements together with the physicochemical properties of nanoparticles (NPs) play a key role in drug transport, and therefore, the MCTS model is appropriate to assess the ability of NP to penetrate the tumor tissue. This review presents recent developments in MCTS models for a better comprehension of the interactions between NPs and tumor components that affect tumor drug delivery. MCTS is particularly suitable for the high-throughput screening of new nanodrugs.

1 June 2019 in Journal of Controlled Release
Verified
Journal Article
Closed access
Ilya YakavetsIlya Yakavets
Ilya Yakavets
MMMarie Millard
Marie Millard
VZVladimir Zorin
Vladimir Zorin
HLHenri-Pierre Lassalle
Henri-Pierre Lassalle
LBLina Bezdetnaya
Lina Bezdetnaya

1 January 2018 in Drug Delivery
Verified
Journal Article
Open access
MMMarie Millard
Marie Millard
Ilya YakavetsIlya Yakavets
Ilya Yakavets
MPMax Piffoux
Max Piffoux
ABAmanda Brun
Amanda Brun
FGFlorence Gazeau
Florence Gazeau
LBLina Bezdetnaya
Lina Bezdetnaya
Efficient photodynamic therapy with meta-tetra(hydroxyphenyl)chlorine requires the application of specific nanoformulations. mTHPC liposomal formulation (Foslip®) demonstrated favorable pharmacokinetics properties. However, rapid liposomes destruction in circulation and rapid mTHPC release impedes Foslip® applications. Alternatively, mTHPC nanovectorization using extracellular vesicles (EVs) could be an attractive option. EVs are naturally secreted by the organism to play a role in intercellular communication due to the capacity to transport proteins and nucleic acids. EVs also possess a natural ability to deliver therapeutic molecules into cancer cells. The aim of the present study was to evaluate photophysical and photobiological properties of mTHPC loaded in endothelial EVs as nanocarriers. We also studied efficiency of nanovectorisation on mTHPC distribution and PDT activity in multicellular tumor spheroids (MCTSs). MCTS is a nonvascularized in vitro 3D model of cells that mimics a similar microenvironment to in vivo situation. mTHPC-EVs were characterized by means of spectroscopic techniques, flow cytometry and nanoparticle tracking analysis. Compared with Foslip®, mTHPC-EVs are stable in murine plasma. Better mTHPC accumulation and penetration (up to 100 µm) in MCTS was observed for mTHPC-EVs compared with liposomal mTHPC. These factors could explain enhanced photodynamic activity of mTHPC-EVs compared with free and liposomal mTHPC. The light dose inducing 50% of cell death with mTHPC-EVs was 4 and 2.5-times lower than that of free and liposomal mTHPC. The obtained results demonstrate that EVs should be considered as perspective nanocarriers for mTHPC-mediated PDT.

15 October 2019 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Ilya YakavetsIlya Yakavets
Ilya Yakavets
SJSamuel Jenard
Samuel Jenard
AFAurelie Francois
Aurelie Francois
YMYulia Maklygina
Yulia Maklygina
Victor LoschenovVictor Loschenov
Victor Loschenov
LBLina Bezdetnaya
Lina Bezdetnaya
Conventional 3D multicellular tumor spheroids of head and neck squamous cell carcinoma (HNSCC) consisting exclusively of cancer cells have some limitations. They are compact cell aggregates that do not interact with their extracellular milieu, thus suffering from both insufficient extracellular matrix (ECM) deposition and absence of different types of stromal cells. In order to better mimic in vivo HNSCC tumor microenvironment, we have constructed a 3D stroma-rich in vitro model of HNSCC, using cancer-associated MeWo skin fibroblasts and FaDu pharynx squamous cell carcinoma. The expression of stromal components in heterospheroids was confirmed by immunochemical staining. The generated co-culture FaDu/MeWo spheroids were applied to study penetration, distribution and antitumor efficacy of photoactive drugs such as Temoporfin and Chlorin e6 used in the photodynamic therapy flow cytometry and fluorescence microscopy techniques. We also investigated the distribution of photodiagnostic agent Indocyanine Green. We demonstrated that the presence of stroma influences the behavior of photoactive drugs in different ways: (i) No effect on Indocyanine Green distribution; (ii) lower accumulation of Chlorin e6; (iii) better penetration and PDT efficiency of Temoporfin. Overall, the developed stroma-rich spheroids enlarge the arsenal of in vitro pre-clinical models for high-throughput screening of anti-cancer drugs.

22 April 2022 in ACS Nano
Verified
Journal Article
Closed access
ANAnastasiya Navrotskaya
Anastasiya Navrotskaya
DADarya Aleksandrova
Darya Aleksandrova
MCMahshid Chekini
Mahshid Chekini
Ilya YakavetsIlya Yakavets
Ilya Yakavets
SKSina Kheiri
Sina Kheiri
EKEugenia Kumacheva
Eugenia Kumacheva

1 August 2016 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
IYIgor Yankovsky
Igor Yankovsky
EBEstelle Bastien
Estelle Bastien
Ilya YakavetsIlya Yakavets
Ilya Yakavets
IKIvan Khludeyev
Ivan Khludeyev
HLHenri-Pierre Lassalle
Henri-Pierre Lassalle
VZVladimir Zorin
Vladimir Zorin